STRO Sutro Biopharma (STRO) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001382101
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
64
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $0 priced
Sutro Biopharma insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for SUTRO BIOPHARMA, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 23.7% of the 71,832 shares held after it.
- 4 other insiders bought within 30 days.
- 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF SCIENTIFIC OFFICER Gerber Hans-Peter bought about $13.6K of STRO on Oct 15, 2025, the largest insider purchase at the company since 2022; 4 other insiders bought within 30 days and 64 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 19,750 shares held after it.
- 4 other insiders bought within 30 days.
- 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO Chow Gregory K. bought about $16.0K of STRO on Oct 15, 2025, the largest insider purchase at the company since 2022; 4 other insiders bought within 30 days and 64 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 10.2% of the 122,850 shares held after it.
- 4 other insiders bought within 30 days.
- 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Chung Jane bought about $10.0K of STRO on Oct 15, 2025, the largest insider purchase at the company since 2022; 4 other insiders bought within 30 days and 64 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 50,000 shares held after it.
- 4 other insiders bought within 30 days.
- 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director MATSUI CONNIE bought about $40.0K of STRO on Oct 15, 2025, the largest insider purchase at the company since 2022; 4 other insiders bought within 30 days and 64 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 17.4% of the 71,737 shares held after it.
- 4 other insiders bought within 30 days.
- 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Admin. Ofcr. & GC Pauling David bought about $10.0K of STRO on Oct 15, 2025, the largest insider purchase at the company since 2022; 4 other insiders bought within 30 days and 64 funds added in the latest 13F quarter.10 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
64 funds bought in last quarter
more than 53% of Pharma & Biotech
Revenue
+65.2% year over year
more than 80% of Pharma & Biotech
Margin
-186.5% net margin
below 64% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
17.2% of the float short (float per yahoo 2026-10-26) · 6.5 days to cover · settled 2026-09-30
more than 75% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch STRO
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-19.6%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns STRO: institutional holders (13F)
13F holdings, latest reported quarter
1,304,846 sh
$43.3M
1,251,788 sh
$41.6M
1,172,487 sh
$38.9M
1,122,655 sh
$37.3M
1,062,872 sh
$35.3M
Congress trades in STRO
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
STRO planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
STRO mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Eventide Healthcare & Life Sciences Fund
$19.4M position · as of 2026-06-30
1.1%
Goldman Sachs Small Cap Equity Insights Fund
$1.9M position · as of 2026-07-31
0.2%
LVIP JPMorgan Small Cap Core Fund
$446.1K position · as of 2026-06-30
0.2%
JPMorgan U.S. Small Company Fund
$2.0M position · as of 2026-06-30
0.2%
NVIT GS Small Cap Equity Insights Fund
$343.5K position · as of 2026-06-30
0.2%
Goldman Sachs Small Cap Value Insights Fund
$1.6M position · as of 2026-07-31
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
8 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
5
Phase 1
2 active
1
Phase 2
0 active
2
Multi-phase
0 active
What changed recently
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or M
2026-10-24 · Not Yet Recruiting → Recruiting
Phase 1
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2022
$3.0M
-$307.0K
$1.5M
-63%
n/a
2021
$5.6M
$1.6M
$3.1M
-31%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 64 funds added last quarter. Each figure is a federal filing, dated the day it went public.
STRO financials
Revenue growth
+65.2%
XBRL, annual
Net margin
-186.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$45.7M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM STRO
| FY Dec 2025 | $102.5M |
| FY Dec 2024 | $62.0M |
| FY Dec 2023 | $153.7M |
| FY Dec 2022 | $67.8M |
| FY Dec 2021 | $61.9M |
| Jun 2026 | $9.8M |
| Mar 2026 | $14.5M |
| Dec 2025 | $11.6M |
| Sep 2025 | $9.7M |
| Jun 2025 | $63.7M |
| Mar 2025 | $17.4M |
| Dec 2024 | $14.8M |
| Sep 2024 | $8.5M |
At each fiscal year end
Single quarter
Net margin, TTM
-395.1%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM STRO
| FY Dec 2025 | -186.4% |
| FY Dec 2024 | -365.9% |
| FY Dec 2023 | -69.6% |
| FY Dec 2022 | -175.9% |
| FY Dec 2021 | -170.6% |
| Jun 2026 | -391.6% |
| Mar 2026 | -265.0% |
| Dec 2025 | -400.8% |
| Sep 2025 | -586.6% |
| Jun 2025 | -18.0% |
| Mar 2025 | -436.6% |
| Dec 2024 | -486.1% |
| Sep 2024 | -572.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM STRO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity STRO
| FY Dec 2025 | n/a |
| FY Dec 2024 | 0.09x |
| FY Dec 2023 | 0.03x |
| FY Dec 2022 | 0.07x |
| FY Dec 2021 | 0.10x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | 0.09x |
| Sep 2024 | 0.04x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-35.75x
TTM operating cash flow over long-term 2023-12-31 (30 months older than the period end) plus current 2023-12-31 (30 months older than the period end)
Cash flow to debt STRO
| FY Dec 2025 | -43.64x |
| FY Dec 2024 | -47.17x |
| FY Dec 2023 | -27.48x |
| FY Dec 2022 | 0.22x |
| FY Dec 2021 | -3.25x |
| Jun 2026 | -35.75x |
| Mar 2026 | -37.33x |
| Dec 2025 | -43.64x |
| Sep 2025 | -54.80x |
| Jun 2025 | -61.28x |
| Mar 2025 | -47.94x |
| Dec 2024 | -47.17x |
| Sep 2024 | -26.04x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity STRO
| FY Dec 2025 | n/a |
| FY Dec 2024 | -233.7% |
| FY Dec 2023 | -58.4% |
| FY Dec 2022 | -50.8% |
| FY Dec 2021 | -36.1% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -1,806% |
| Jun 2025 | -346.9% |
| Mar 2025 | -677.9% |
| Dec 2024 | -233.7% |
| Sep 2024 | -111.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-79.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets STRO
| FY Dec 2025 | -68.1% |
| FY Dec 2024 | -52.9% |
| FY Dec 2023 | -24.4% |
| FY Dec 2022 | -31.9% |
| FY Dec 2021 | -28.7% |
| Jun 2026 | -79.0% |
| Mar 2026 | -54.5% |
| Dec 2025 | -68.1% |
| Sep 2025 | -65.4% |
| Jun 2025 | -55.4% |
| Mar 2025 | -67.5% |
| Dec 2024 | -52.9% |
| Sep 2024 | -28.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital STRO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-88.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed STRO
| FY Dec 2025 | -89.5% |
| FY Dec 2024 | -75.4% |
| FY Dec 2023 | -24.9% |
| FY Dec 2022 | -40.3% |
| FY Dec 2021 | -29.7% |
| Jun 2026 | -88.6% |
| Mar 2026 | -66.5% |
| Dec 2025 | -89.5% |
| Sep 2025 | -81.0% |
| Jun 2025 | -74.9% |
| Mar 2025 | -97.8% |
| Dec 2024 | -75.4% |
| Sep 2024 | -38.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing STRO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$104.4M
market value at close 2026-10-23 on 2026-08-07 shares, plus long-term 2023-12-31 (30 months older than the period end) plus current 2023-12-31 (30 months older than the period end), minus cash 2026-06-30
Enterprise value STRO
| FY Dec 2025 | $930.9M |
| FY Dec 2024 | $1.3B |
| FY Dec 2023 | $2.5B |
| FY Dec 2022 | $4.6B |
| FY Dec 2021 | $6.9B |
| Jun 2026 | $499.9M |
| Mar 2026 | $343.1M |
| Dec 2025 | $930.9M |
| Sep 2025 | $675.7M |
| Jun 2025 | $539.7M |
| Mar 2025 | $442.4M |
| Dec 2024 | $1.3B |
| Sep 2024 | $2.7B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield STRO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing STRO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $102.5M | $62.0M | $153.7M | $67.8M |
| Operating income | -$158.4M | -$238.5M | -$89.3M | -$128.9M |
| Net income | -$191.0M | -$227.0M | -$107.0M | -$119.2M |
| EPS (diluted) | -22.49 | -29.40 | -1.78 | -2.35 |
| Operating cash flow | -$177.2M | -$191.5M | -$111.6M | $3.5M |
| Cash | $58.1M | $190.3M | $69.3M | $47.3M |
| Long-term debt | n/a | n/a | $0 | $3.8M |
SEC XBRL, fiscal years, as known on 2026-10-27
STRO Stock Sonar score 5/7 axes
Find similar shapesCompareSTRO ranks highest on growth (80th percentile) and institutional and government (53rd), and lowest on financial health (14th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
